USAEUROPEViVE
ABOUTSPONSORSHIPFOUNDATION
Logo Hlth
Logo Hlth
20 Jan 2022 | 03:45 PM GMT

The Power of RWE in Pharma companies: improving discovery and development

Anchored by:

Myles Furnace
Chief Commercial Officer
EOLAS MEDICAL

Participants:

Myles Furnace Chief Commercial OfficerEolas Medical
Myles Furnace
Chief Commercial OfficerEolas Medical
Aahuti Rai NED, Advisor & Venture PartnerFour Points Health | Conduit Connect
Aahuti Rai
NED, Advisor & Venture PartnerFour Points Health | Conduit Connect
Abhishek Shah Co-Founder & CEOWellthy Therapeutics Pvt. Ltd.
Abhishek Shah
Co-Founder & CEOWellthy Therapeutics Pvt. Ltd.
Gabriel Koslover Strategic InitiativesuMed
Gabriel Koslover
Strategic InitiativesuMed
George Platings Director of Business DevelopmentuMotif
George Platings
Director of Business DevelopmentuMotif
JM
john mattison CMIOACP
JM
john mattison
CMIOACP
JD
John David (J.D.) McCullough Commercial Operating PartnerAegis Ventures
JD
John David (J.D.) McCullough
Commercial Operating PartnerAegis Ventures
Matt Norton VP of Marketing & Commercial DevelopmentS3 Connected Health
Matt Norton
VP of Marketing & Commercial DevelopmentS3 Connected Health
Nikos Green Senior Venture Architect & PO NeuroscienceRoX Health GmbH
Nikos Green
Senior Venture Architect & PO NeuroscienceRoX Health GmbH
Zina Manji Founder/Principal, Regulatory StrategistInnopathwayz, LLC
Zina Manji
Founder/Principal, Regulatory StrategistInnopathwayz, LLC

About this Meeting

How should RWE solutions evolve to accelerate Pharma discovery and development? Join this meeting to discuss this with other senior leaders. More specifically we will talk about:  

  •  What are the best use cases of RWE in drug research and development?
  •  Are clinical and R&D teams in pharma companies using RWE? Challenges & Barriers when incorporating RWE in pharma teams for discovery and development. What role do RWD platforms play?
  •   There are tons of companies building RWD platforms, how can they differentiate? What capabilities are missing?  
  •  Some RWD vendors are offering free clinical data (e.g. IQVIA, OPTUM) and more pharma companies are bringing advanced analytics in-house. What services are lacking to take these RWD offerings and turn them into tangible value for pharma?